# Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

> **NCT05223478** · PHASE3 · COMPLETED · sponsor: **Ocuphire Pharma, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Mydriasis
- Dilation

## Interventions

- **DRUG:** Phentolamine Ophthalmic Solution 0.75%
- **DRUG:** Phentolamine Ophthalmic Solution Vehicle

## Key facts

- **NCT ID:** NCT05223478
- **Lead sponsor:** Ocuphire Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-17
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-04-28
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223478, "Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05223478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*